Evidence map›Paper›PMID 39671020›Full record

ReviewJournal of neuro-oncology2025

Circulating biomarkers in high-grade gliomas: current insights and future perspectives.

Suchet Taori, Ahmed Habib, Samuel Adida, Neslihan Nisa Gecici, Nikhil Sharma, Michael Calcaterra, Anthony Tang, Sumaarg Pandya, Arnav Mehra, Hansen Deng and 4 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Current Status and Evolution of Immunotherapy in Glioma Management.International journal of medical sciences · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Suchet TaoriSchool of Medicine, University of Pittsburgh, Pennsylvania, PA, USA.
Ahmed HabibDepartment of Neurological Surgery, University of Pittsburgh Medical Center, Pennsylvania, PA, USA.
Samuel AdidaSchool of Medicine, University of Pittsburgh, Pennsylvania, PA, USA.
Neslihan Nisa GeciciDepartment of Neurological Surgery, University of Pittsburgh Medical Center, Pennsylvania, PA, USA.
Nikhil SharmaDepartment of Neurological Surgery, University of Pittsburgh Medical Center, Pennsylvania, PA, USA.
Michael CalcaterraSchool of Medicine, University of Pittsburgh, Pennsylvania, PA, USA.
Anthony TangSchool of Medicine, University of Pittsburgh, Pennsylvania, PA, USA.
Sumaarg PandyaSchool of Medicine, University of Pittsburgh, Pennsylvania, PA, USA.
Arnav MehraSchool of Medicine, University of Pittsburgh, Pennsylvania, PA, USA.
Hansen DengDepartment of Neurological Surgery, University of Pittsburgh Medical Center, Pennsylvania, PA, USA.
Hayat ElidrissyDepartment of Neurological Surgery, University of Pittsburgh Medical Center, Pennsylvania, PA, USA.
Yassine Alami IdrissiDepartment of Neurological Surgery, University of Pittsburgh Medical Center, Pennsylvania, PA, USA.
Mohammadreza AmjadzadehDepartment of Neurological Surgery, University of Pittsburgh Medical Center, Pennsylvania, PA, USA.
Pascal O ZinnSchool of Medicine, University of Pittsburgh, Pennsylvania, PA, USA. zinnpo@pitt.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeHigh-grade gliomas (HGG) represent a challenging subset of brain tumors characterized by aggressive nature and poor prognosis. Histopathology remains to be the standard for diagnosis, however, it is invasive, prone to sampling errors, and may not capture the full tumor heterogeneity and evolution over time. In recent years, there has been a growing interest in the potential utility of circulating biomarkers, obtained through minimally-invasive liquid biopsies, providing an opportunity for diagnosis, prognostication, monitoring treatment response and developing targeted therapies.

methodsWe have reviewed the literature on circulating biomarkers for HGG, including circulating tumor cells (CTCs), circulating tumor-derived exosomes/extracellular vesicles (ctEVs), circulating tumor-derived DNA (ctDNA), circulating tumor-derived miRNA (ctmiRNA), and circulating tumor-derived proteins.

resultsCTCs provide real-time information about tumor characteristics for molecular profiling and monitoring treatment response, yet their low numbers in circulation makes detection challenging. ctEVs carry a range of biomolecules and are easily detectable. However, they are not exclusively released from tumor cells and heterogeneity in their content requires standardized isolation and analysis methods. ctDNA is another promising biomarker with its levels correlating with the disease stage. However, its low concentration in blood requires highly sensitive techniques for identification and differentiation from normal cell-free DNA. ctmiRNA and tumor-derived proteins show promise but are limited by their susceptibility to dilution and lack of specificity in current technology.

conclusionThis review highlights the transformative potential of circulating biomarkers in the management of HGG, with implications for improving patient outcomes, optimizing treatment strategies, and advancing precision oncology in neuro-oncology practice.

Indexed as

Biomarkers, TumorBrain NeoplasmsGliomaNeoplastic Cells, CirculatingExosomesExtracellular VesiclesHumansNeoplasm GradingBiomarkers, TumorBiomarkerDiagnosticsGliomaLiquid biopsyPrecision medicinePrognosis

Identifiers

PMID39671020

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.